THE IMPORTANCE OF CLINICAL AND INSTRUMENTAL DIAGNOSTIC IN THE MAMMARY GLAND CANCER

Authors

  • E. ANTON University of Medicine and Pharmacy”Grigore T. Popa”- Iasi
  • Natalia BOTNARIUC Oncology Institute-Chisinau, Republic of Moldova
  • E. ANCUTA Cuza Voda Obstetrics and Gynecology Clinical Hospital
  • B. DOROFTEI University of Medicine and Pharmacy”Grigore T. Popa”- Iasi
  • A. CIOBICA Alexandru Ioan Cuza University, Iasi, Romania
  • Carmen ANTON University of Medicine and Pharmacy”Grigore T. Popa”- Iasi

Abstract

Breast cancer is the most common oncology disease in women and is one of the major public health issues. Worldwide, is the second leading cause of cancer death in women and cancer research is a priority in all the laboratories of the world, in terms of uncovering the appearance causes of the malignant process, understanding the mechanisms of development, but most of all, the discovery of early diagnostic methods and effective treatment. Ignorance, fear of diagnosis, lack of health education and of efficient programmes for prevention and screening could cause diagnosis of the disease to be detected in the majority of cases in advanced stages, when treatment remains only palliative and very costly, in this cases the patient's suffering being immense. In this way, regarding the clinical diagnosis in stage I mammary gland cancer, in the 496 stage I MGC patients, during the primary clinical investigation the diagnosis of stage I MGC was established only in 165 (33.3%) patients, and in 232 (46,8%) patients the diagnosis of suspicion MGC was obtained. Also, in terms of instrumental diagnosis, such as mammography, ultrasonography in mammary gland cancer stage I, it seems that in accordance with literature data the pathological process features assessment in the mammary gland is problematic especially in young age. Thus, it seems that MGC represents a polymorphic and pathogenic disease and it cannot be admitted that all subgroups of patients will obtain identical results from one tactic of treatment determined for all the patients with MGC. In this way, the concept of MGC both clinical and patho morphological, combines different cell clones depending on its microstructure and biology. As a result, the evolution of the disease, the prognosis and the effectiveness of the treatment may vary in different patients at the same stage, depending on the degree of malignancy of the tumor, its histopathological structure, the degree of expression of molecular markers identification and also immune resistance.

Author Biographies

  • E. ANTON, University of Medicine and Pharmacy”Grigore T. Popa”- Iasi

    Faculty of Medicine

  • E. ANCUTA, Cuza Voda Obstetrics and Gynecology Clinical Hospital

    Research Department

  • B. DOROFTEI, University of Medicine and Pharmacy”Grigore T. Popa”- Iasi

    Faculty of Medicine

  • Carmen ANTON, University of Medicine and Pharmacy”Grigore T. Popa”- Iasi

    Faculty of Medicine

References

1. Baselga J., Zambetti M. and A. Lombart-Cussac. Phase II genomics study of ixabepilone as neoadju-vant treatment for breast cancer. J Clin Oncol 2009; 27: 526-534.
2. Charafe-Jauffret E., Ginestier C. and F. Iovino. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res, 2009; 69: 1302-1313.
3. Colleoni M., Rotmensz N. and G. Peruzzotti. Minimal and small size invasive breast cancer with no axillary lymph node involvement, the need for tailored adjuvant therapies. Ann Oncol 2004; 15: 1633-1639.
4. Devi K., Kuruvila S and M. Musa. Pathological pronostic factors in breast carcinoma. Saudi Med J 2000; 21: 372.
5. Fisher B., Redmond C and R. Poisson. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. Engl. J. Med, 1989; 320: 822-828.
6. Fitsgibbons PL. Breast cancer. Pronostic factors in cancer (2nd ed.), London, 2001; 467-486.
7. Goldhirsch A, Wood WC and R. Gelber. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
8. Hamilton A. and M. Piccart. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann. Oncol 2000; 11: 647-663.
9. Hughes K.S., Schnaper D. and D. Berry. Comparison of lumpectomy plus tamoxifen with and without radiotherapy (RT) in women 70 years of age or older who have clinical stage I estrogen receptor posi-tive (ER+) breast carcinoma Proc. Am. Soc. Clin. Oncol, 2001; 20: 93.
10. Leitner S.P., Swerh A.S. and D. Weinberger. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer. Cancer 1995; 76: 2266-2274.
11. McCloud P (2009). Slide presentation during the 11th International Conference on Primary Therapy of Early Breast Cancer, 11-14 March 2009, St Gallen, Switzerlend.
12. Rosen P.P., Groshen S. and P. Saigo. Pathological pronostic factors in stage I and stage II breast carci-noma: a study of 644 patients with median follow- up of 18 years. J. Clin. Oncol 1999; 7: 1239-1251.
13. Spooner D. Role of radiotherapy in early breast cancer (stage I). A west Midlands Breast Group prospective randomized colloborative study (BR3002). British Journal of Cancer, 1997; 76: 17.
14. Vitucci C., Tirelli C. and F. Graciano. Results of Conservative Surgery for Limited-Sized Infiltrating Brest Cancer: Analysis of 962 Tested Patients: 24 Years of Experience. Journal of Surgical Oncology, 2000; 74: 108-115.

Additional Files

Published

2015-06-30

Issue

Vol. 119 No. 2 (2015): The Medical-Surgical Journal

Section

SURGERY

License

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form